Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oragenics, Inc. (OGEN : AMEX)

• Company Description    Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.43 Daily Weekly Monthly 20 Day Moving Average: 1,248,135 shares Shares Outstanding: 0.82 (millions) Market Capitalization: $1.18 (millions) Beta: 0.95 52 Week High: $75.60 52 Week Low: $1.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -61.46% -63.39% 12 Week -75.47% -78.63% Year To Date -87.11% -87.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1990 MAIN STREET SUITE 750 - SARASOTA,FL 34236 USA ph: 813-286-7900 fax: 813-286-7904 None http://www.oragenics.com

• General Corporate Information    Officers Kimberly M. Murphy - Chief Executive Officer; Chief Financial Officer; Charles L. Pope - Executive Chairman and Director Joseph Michael Redmond - Interim Principal Executive Officer; President Robert C. Koski - Director Frederick W. Telling - Director Peer Information Oragenics, Inc. (CORR.) Oragenics, Inc. (RSPI) Oragenics, Inc. (CGXP) Oragenics, Inc. (BGEN) Oragenics, Inc. (GTBP) Oragenics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 684023609 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 0.82 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.95 Market Capitalization: $1.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 82.86% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -3,614.27 12/31/24 - -2,074.19 ROA 06/30/25 - - 03/31/25 - -311.83 12/31/24 - -327.16 Current Ratio 06/30/25 - - 03/31/25 - 1.04 12/31/24 - 0.87 Quick Ratio 06/30/25 - - 03/31/25 - 1.04 12/31/24 - 0.87 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.19 12/31/24 - -0.51 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - -

Powered by Zacks Investment Research ©